These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

126 related articles for article (PubMed ID: 36301466)

  • 1. Articles You May Have Missed.
    Adkins A; Trautman W
    J Med Toxicol; 2023 Jan; 19(1):49-52. PubMed ID: 36301466
    [No Abstract]   [Full Text] [Related]  

  • 2. Comment on Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens.
    Jefri MY; Nelson LS
    Clin Toxicol (Phila); 2021 Jan; 59(1):79-80. PubMed ID: 33156706
    [No Abstract]   [Full Text] [Related]  

  • 3. Authors' reply to Comment on Comparison of rates of opioid withdrawal symptoms and reversal of opioid toxicity in patients treated with two naloxone dosing regimens.
    Purssell R; Godwin J; Moe J; Buxton J; Kestler A; Brubacher JR
    Clin Toxicol (Phila); 2021 Jan; 59(1):80-81. PubMed ID: 33215939
    [No Abstract]   [Full Text] [Related]  

  • 4. Activation of serotonin 5-HT(2C) receptor suppresses behavioral sensitization and naloxone-precipitated withdrawal symptoms in morphine-dependent mice.
    Zhang G; Wu X; Zhang YM; Liu H; Jiang Q; Pang G; Tao X; Dong L; Stackman RW
    Neuropharmacology; 2016 Feb; 101():246-54. PubMed ID: 26432939
    [TBL] [Abstract][Full Text] [Related]  

  • 5. The relative potency of inverse opioid agonists and a neutral opioid antagonist in precipitated withdrawal and antagonism of analgesia and toxicity.
    Sirohi S; Dighe SV; Madia PA; Yoburn BC
    J Pharmacol Exp Ther; 2009 Aug; 330(2):513-9. PubMed ID: 19435929
    [TBL] [Abstract][Full Text] [Related]  

  • 6. High-dose buprenorphine for treatment of high potency opioid use disorder.
    Danilewitz M; McLean M
    Drug Alcohol Rev; 2020 Feb; 39(2):135-137. PubMed ID: 31769109
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Buprenorphine therapy in the setting of induced opioid withdrawal from oral naltrexone: a case report.
    Szczesniak LM; Calleo VJ; Sullivan RW
    Harm Reduct J; 2020 Oct; 17(1):71. PubMed ID: 33028340
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Ultrarapid opioid detoxification of two children with congenital heart disease.
    Greenberg M
    J Addict Dis; 2000; 19(4):53-8. PubMed ID: 11110064
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A double-blind, double-dummy, randomized controlled study of memantine versus buprenorphine in naloxone-precipitated acute withdrawal in heroin addicts.
    Jain K; Jain R; Dhawan A
    J Opioid Manag; 2011; 7(1):11-20. PubMed ID: 21434580
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Naloxone-Induced Acute Opioid Withdrawal in a Stabilized Extended-Release Naltrexone-Treated Patient.
    Spitzberg AJ; Urner EM; Wirshing WC
    Prim Care Companion CNS Disord; 2020 Sep; 22(5):. PubMed ID: 32942347
    [No Abstract]   [Full Text] [Related]  

  • 11. Dose-dependent naloxone-induced morphine withdrawal symptoms in opioid-dependent males-a double-blinded, randomized study.
    Weisshaar S; Brandt L; Litschauer B; Sheik-Rezaei S; Moser L; Nirnberger G; Kühberger E; Bauer U; Firbas C; Gouya G; Wolzt M; Fischer G
    Br J Clin Pharmacol; 2020 Aug; 86(8):1610-1619. PubMed ID: 32145041
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A competent and compassionate approach to opioid withdrawal in hospital.
    Bray J
    BMJ; 2023 Feb; 380():396. PubMed ID: 36810193
    [No Abstract]   [Full Text] [Related]  

  • 13. Ondansetron does not prevent physical dependence in patients taking opioid medications chronically for pain control.
    Chu LF; Rico T; Cornell E; Obasi H; Encisco EM; Vertelney H; Gamble JG; Crawford CW; Sun J; Clemenson A; Erlendson MJ; Okada R; Carroll I; Clark JD
    Drug Alcohol Depend; 2018 Feb; 183():176-183. PubMed ID: 29278818
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Evaluation of the effects of lofexidine and clonidine on naloxone-precipitated withdrawal in opioid-dependent humans.
    Walsh SL; Strain EC; Bigelow GE
    Addiction; 2003 Apr; 98(4):427-39. PubMed ID: 12653813
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Modest opioid withdrawal suppression efficacy of oral tramadol in humans.
    Lofwall MR; Walsh SL; Bigelow GE; Strain EC
    Psychopharmacology (Berl); 2007 Oct; 194(3):381-93. PubMed ID: 17605004
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Novel Oral Nanoparticle Formulation of Sustained Release Naloxone with Mild Withdrawal Symptoms in Mice.
    Madison CA; Arora M; Kumar MNVR; Eitan S
    ACS Chem Neurosci; 2020 Jul; 11(13):1955-1964. PubMed ID: 32491828
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Preventing withdrawal syndrome.
    Whedon M
    Nursing; 1995 Dec; 25(12):59. PubMed ID: 8552343
    [No Abstract]   [Full Text] [Related]  

  • 18. In vivo and in vitro attenuation of naloxone-precipitated experimental opioid withdrawal syndrome by insulin and selective KATP channel modulator.
    Singh P; Sharma B; Gupta S; Sharma BM
    Psychopharmacology (Berl); 2015 Jan; 232(2):465-75. PubMed ID: 25059539
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Suvorexant ameliorated sleep disturbance, opioid withdrawal, and craving during a buprenorphine taper.
    Huhn AS; Finan PH; Gamaldo CE; Hammond AS; Umbricht A; Bergeria CL; Strain EC; Dunn KE
    Sci Transl Med; 2022 Jun; 14(650):eabn8238. PubMed ID: 35731889
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Naloxone in Out-of-Hospital Cardiac Arrest-More Than Just Opioid Reversal.
    Wampler DA
    JAMA Netw Open; 2024 Aug; 7(8):e2429131. PubMed ID: 39163048
    [No Abstract]   [Full Text] [Related]  

    [Next]    [New Search]
    of 7.